Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Recruiting

Phase 1

Nivolumab & BMS-986253Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma

Sponsor:

Yana Najjar

Code:

NCT04572451

Conditions

Melanoma

Unresectable Solid Tumors

Neoplasms

Neoplasms by Histologic Type

Neoplasms by Site

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

nivolumab

BMS-986253

Stereotactic Body Radiotherapy (SBRT)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-01-11. This information was provided to ClinicalTrials.gov by Yana Najjar on 2025-08-01.